However, CDR2L is now recognized as the major Yo antigen, as the detection of CDR2L in cell-based assays was shown to be more reliable for the diagnosis of PCD than the CDR2 antigen test which has a specificity for anti-Yo as low as 8% [21]. The gene discussed is CDR2; the disease is paraneoplastic neurologic syndrome.